Jpmorgan Chase & CO Humacyte, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Humacyte, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 51,835 shares of HUMA stock, worth $250,881. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,835
Previous 52,191
0.68%
Holding current value
$250,881
Previous $250,000
12.4%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding HUMA
# of Institutions
150Shares Held
35.1MCall Options Held
279KPut Options Held
607K-
Black Rock Inc. New York, NY7.14MShares$34.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.06MShares$24.5 Million0.0% of portfolio
-
State Street Corp Boston, MA4.76MShares$23.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$9.87 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.27MShares$6.13 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $499M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...